Anthropic Adds Novartis CEO Vas Narasimhan to Its Board—Here’s Why That Matters

Anthropic just made a board appointment that actually makes sense if you think about where AI is headed. Vas Narasimhan, the CEO of Novartis and a physician-scientist by training, is joining the company’s Board of Directors. But here’s the twist—he wasn’t appointed by the usual shareholders. This came from Anthropic’s Long-Term Benefit Trust, that independent body with zero financial stake in the company.

Daniela Amodei, Anthropic’s co-founder and president, put it better than I could: “Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years.” She’s not wrong. Narasimhan has overseen the development and approval of more than 35 novel medicines. That’s not just a resume bullet point—that’s navigating one of the most regulated industries on the planet while still delivering results.

This appointment nudges the Trust-appointed directors into a majority on the board. That’s a governance structure most tech companies wouldn’t touch with a ten-foot pole. The Trust exists to keep Anthropic’s mission—developing AI for the long-term benefit of humanity—from getting steamrolled by profit pressure. Having a majority of directors who aren’t financially tied to the company’s stock price? That’s rare, and honestly, it’s refreshing.

Narasimhan’s background is particularly relevant here. Early in his career, he worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He’s an elected member of the US National Academy of Medicine. He chairs the board of fellows at Harvard Medical School. This isn’t someone who just runs a pharma company—he’s been on the ground where technology meets human suffering.

“Working across medicine, innovation, and global health has shown me the transformative potential of technology when deployed responsibly,” Narasimhan said. That’s not just corporate speak. Healthcare and life sciences are arguably where AI can have the most immediate, tangible impact. Drug discovery, disease biology, personalized medicine—these are areas where Claude and models like it could genuinely save lives, not just optimize ad targeting.

Neil “Buddy” Shah, chair of the Trust, summed up the rationale: “Vas has spent his career stewarding breakthrough science responsibly—exactly the perspective we are excited to have on the board.” The key word there is “responsibly.” Anthropic has been hammering the safety-first approach since day one, and this appointment reinforces that.

Narasimhan joins a board that already includes Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. It’s a solid mix of tech veterans and governance experience, but Narasimhan brings something the others don’t: deep domain expertise in a field where AI could either do immense good or cause serious harm if deployed carelessly.

I’ll be watching to see how this plays out. Having a pharma CEO on the board doesn’t guarantee anything, but it signals that Anthropic is serious about healthcare applications. And given how much hype surrounds AI in medicine right now, having someone who’s actually navigated regulatory approval for novel treatments is a practical move, not just a PR one.